Highlights ContraFect Corporation

Equities

CFRXQ

US2123264093

Market Closed - OTC Markets Other stock markets 13:57:25 2024-07-05 EDT			5-day change	1st Jan Change
0.0151 ^USD	+0.67%		-27.75%	-49.67%

05-03	North American Morning Briefing : Apple, Amgen -2-	DJ
04-26	North American Morning Briefing : Tech Still in -2-	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Apple, Amgen -2-	05-03	DJ
North American Morning Briefing : Tech Still in -2-	04-26	DJ
North American Morning Briefing : Stock Futures -2-	04-19	DJ
ContraFect Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
ContraFect Submits Investigational New Drug Application for Bacterial Pneumonia Treatment	23-09-18	MT
ContraFect Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
ContraFect Corporation Presents Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company's Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-Neg Pathogens	23-06-20	CI
ContraFect Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Contrafect Corporation Announces First Patient Dosed in the Phase 1B/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee	23-04-26	CI
ContraFect Corporation Announces Data Presentations at 33rd Annual ECCMID Meeting Highlight Potential Efficacy of Lysins CF-370 Against Antibiotic Resistant Gram-Negative Pathogens	23-04-20	CI
ContraFect Corporation Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee	23-04-03	CI
ContraFect Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
ContraFect Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-31	CI
ContraFect Corporation Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase	22-12-19	CI
ContraFect Says French Regulator Approves Trial Application for Exebacase to Treat Prosthetic Joint Infection of Knee	22-11-28	MT
ContraFect Corporation Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections	22-11-28	CI
ContraFect Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections	22-09-12	CI
ContraFect Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
North American Morning Briefing : Stock Futures -2-	22-08-12	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ContraFect Corporation

Equities

CFRXQ

US2123264093

Highlights

Filters